Table I. Baseline characteristics, by incident hospitalization.

	Overall (n = 9484)	No hospitalization (n = 6521)	Any hospitalization (n = 2963)	P
Age (y)	75 (67–82)	75 (67–81)	76 (68–82)	<.0001
Female	43	42	44	.046
Race				.17
White	90	89	91
Black or African American	4.7	4.8	4.6
Hispanic	4.1	4.3	3.6
Other	1.4	1.5	1.2
Health insurance status				.0002
Medicare or Medicaid	70	69	73
Private	25	26	22
Other	4.7	4.8	4.4
Hypertension	83	82	85	.0006
Hyperlipidemia	73	72	74	.12
Diabetes	29	27	35	<.0001
Peripheral vascular disease	13	12	17	<.0001
Coronary artery disease	33	29	39	<.0001
Heart failure				<.0001
None	67	72	57
NYHA I	10	9.9	11
NYHA II	15	13	20
NYHA III/IV	7.4	5.5	11
Prior cerebrovascular events (stroke or TIA)	15	14	17	<.0001
Left ventricular ejection fraction				<.0001
>50%	70	72	68
40%–50%	6.3	5.8	7.5
30%–40%	8.9	7.9	11
<30%	4.3	3.6	5.7
Calculated glomerular filtration rate (mL/min per 1.73 m2	67 (53–82)	68 (55–83)	64 (50–79)	<.0001
AF type at baseline				0.54
New onset	4.4	4.3	4.7
Paroxysmal	51	51	50
Persistent	17	17	17
Long-standing persistent	28	28	29
EHRA symptom class				<.0001
None	38	40	33
Mild	45	45	46
Severe	15	13	18
Disabling	1.8	1.8	1.8
CHADS2 score, mean (SD)	2.3 (1.3)	2.2 (1.3)	2.5 (1.3)	<.0001
Antiarrhythmic therapy at baseline	29	28	31	.003
Any oral anticoagulant	77	76	78	.14
Oral anticoagulant*				.39
None	23	24	22
Warfarin	72	71	73
Dabigatran	4.8	4.9	4.8
Percent time in therapeutic range (INR 2-3), median (IQR)	62 (41–80)	65 (45–83)	54 (36–73)	<.0001
Percent time INR <2, median (IQR)	19 (4–37)	17 (0–34)	25 (9–43)	<.0001
Percent time INR >3, median (IQR)	9 (0–23)	9 (0–22)	12 (0–26)	<.0001

Values are presented as % or median (interquartile range), unless noted otherwise. Time in therapeutic range was calculated using the Rosendaal method.¹⁰

Abbreviations: TIA, transient ischemic attack; IQR, interquartile range.

^*No patients were on rivaroxaban or apixaban at baseline.